Courage Against Cancer
While no food can cure cancer, emerging research suggests that anti-inflammatory foods may play a supporting role in cancer care by potentially helping your body manage inflammation and supporting overall wellness during treatment. Many cancer patients and survivors explore dietary approaches al…
While probiotics show promise for gut health, current evidence doesn’t confirm they prevent colorectal cancer recurrence. However, they may support overall digestive wellness alongside your medical treatment plan.
Current medical guidance suggests 150 minutes of moderate-intensity aerobic activity per week during cancer treatment, when tolerated. However, individual tolerance varies significantly based on treatment type, side effects, and overall health.
Dietary fiber may help reduce colorectal cancer risk by promoting healthy digestion, feeding beneficial gut bacteria, and potentially reducing harmful substances’ contact with the colon. While fiber alone isn’t a cure, it’s part of an evidence-based preventive strategy alongside screening and me…
While no natural compound can guarantee cancer prevention, research suggests certain dietary components—like fiber, polyphenols found in plants, and specific probiotics—may support colorectal health and potentially reduce cancer risk when combined with lifestyle changes.
If you are a colorectal cancer patient considering fenbendazole, the most important first step is an honest, open conversation with your oncologist before starting anything. Evidence-based answers to this question consistently point to the same priority: protect your proven treatment plan while …
This article from Courage Against Cancer evaluates the potential of fenbendazole, a veterinary drug, as a treatment for human colorectal cancer. Despite promising preclinical evidence, there are no conclusive human trials proving its efficacy. Patients are urged to discuss its use with oncologists, as risks such as liver toxicity exist.
Courage Against Cancer clarifies that ivermectin lacks validated clinical evidence as a cancer treatment despite preclinical interest. Major oncology institutions do not endorse it, emphasizing the importance of rigorous evidence-based evaluations. Patients are encouraged to discuss concerns with their oncologists and critically assess claims surrounding off-label treatments.
The article from Courage Against Cancer discusses Joe Tippens, whose recovery from small cell lung cancer was linked to fenbendazole, a veterinary dewormer. It emphasizes that his case lacks clinical validation and critical context, such as concurrent immunotherapy, highlighting the importance of distinguishing personal narratives from scientific evidence in cancer treatment discussions.
As of 2026, the FDA has not approved ivermectin for any cancer treatments; it is only sanctioned for specific parasitic infections. While off-label prescribing is legal, there is no solid evidence supporting its efficacy in oncology. Patients should consult their healthcare providers before altering treatment plans based on unverified claims.